title: The role of peptide and DNA vaccines in myeloid leukemia immunotherapy.
abstract: While chemotherapy and targeted therapy are successful in inducing the remission of myeloid leukemia as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), the disease remains largely incurable. This observation is likely due to the drug resistance of leukemic cells, which are responsible for disease relapse. Myeloid leukemia vaccines may most likely be beneficial for eradicating minimal residual disease after treatment with chemotherapy or targeted therapy. Several targeted immunotherapies using leukemia vaccines have been heavily investigated in clinical and preclinical trials. This review will focus on peptides and DNA vaccines in the context of myeloid leukemias, and optimal strategies for enhancing the efficacy of vaccines based on myeloid leukemia immunization are also summarized.
authors: Department of Microbiology and Immunology, Medical College, Jinan University, Guangzhou, 510632, China. tlinc@jnu.edu.cn.
authors: Chen
authors: C
authors: Lin
authors: Yangqiu
authors: Y
authors: Li
references: Br J Haematol. 2010 Jul;150(2):240-2
references: 20346015
references: J Clin Oncol. 1997 Feb;15(2):433-44
references: 9053463
references: Cancer Res. 2001 Feb 15;61(4):1555-62
references: 11245465
references: Blood. 2008 Oct 1;112(7):2956-64
references: 18502835
references: J Hematol Oncol. 2012 Dec 10;5:74
references: 23228155
references: J Immunol. 1998 Dec 15;161(12):6532-6
references: 9862678
references: Eur Urol. 2000 Aug;38(2):208-17
references: 10895014
references: Blood. 2008 Jan 1;111(1):236-42
references: 17875804
references: Nat Immunol. 2009 Mar;10(3):266-72
references: 19158679
references: Curr Opin Immunol. 2010 Apr;22(2):264-70
references: 20172703
references: Curr Opin Allergy Clin Immunol. 2012 Dec;12(6):648-57
references: 23090384
references: Leukemia. 2006 Oct;20(10):1738-50
references: 16932347
references: Nat Rev Immunol. 2008 Feb;8(2):107-19
references: 18219309
references: Blood. 2009 Jun 25;113(26):6541-8
references: 19389880
references: Blood. 2002 Mar 1;99(5):1517-26
references: 11861263
references: Lancet. 2005 Feb 19-25;365(9460):657-62
references: 15721470
references: Mol Immunol. 2012 Jul;51(3-4):325-31
references: 22525006
references: Haematologica. 2011 Mar;96(3):432-40
references: 21134985
references: Hum Gene Ther. 2003 May 20;14(8):709-14
references: 12804135
references: Int J Oncol. 2009 Oct;35(4):941-51
references: 19724931
references: Blood. 2004 Feb 1;103(3):1037-42
references: 14504104
references: Blood. 2001 Oct 1;98(7):2039-42
references: 11567987
references: Leukemia. 2008 Aug;22(8):1613-6
references: 18256684
references: J Immunother. 2011 Jan;34(1):85-91
references: 21150716
references: J Hematol Oncol. 2011 Nov 14;4:46
references: 22082134
references: Zhonghua Zhong Liu Za Zhi. 2007 Feb;29(2):93-5
references: 17645839
references: Cancer Immunol Immunother. 2012 Mar;61(3):313-22
references: 21898091
references: Blood. 2011 Mar 24;117(12):3353-62
references: 21278353
references: N Engl J Med. 1979 May 10;300(19):1068-73
references: 34792
references: Cancer. 2009 Sep 1;115(17):3924-34
references: 19536894
references: Haematologica. 2005 Aug;90(8):1042-9
references: 16079103
references: J Exp Clin Cancer Res. 1999 Dec;18(4):485-92
references: 10746975
references: Blood. 1996 Oct 1;88(7):2450-7
references: 8839835
references: Med Oncol. 2011 Mar;28(1):219-30
references: 20107936
references: Cancer. 2003 Jul 1;98(1):144-54
references: 12833467
references: Leukemia. 2008 Sep;22(9):1721-7
references: 18548092
references: J Immunol. 2001 Mar 1;166(5):3061-6
references: 11207256
references: Nat Med. 2003 Nov;9(11):1413-7
references: 14566333
references: Cancer Cell Int. 2012 Dec 15;12(1):52
references: 23241263
references: Ann Hematol. 2011 Aug;90(8):901-9
references: 21274712
references: Exp Hematol Oncol. 2012 May 18;1(1):13
references: 23210643
references: Haematologica. 2006 Dec;91(12):1653-61
references: 17145602
references: Int J Cancer. 2004 Feb 20;108(5):704-11
references: 14696097
references: Blood. 2008 Sep 1;112(5):1876-85
references: 18591381
references: Discov Med. 2004 Feb;4(20):41-4
references: 20705019
references: Cancer Res. 2002 Oct 15;62(20):5845-52
references: 12384547
references: Clin Dev Immunol. 2011;2011:176759
references: 22028727
references: Hematology. 2010 Apr;15(2):88-95
references: 20423569
references: J Hematol Oncol. 2012 Sep 16;5:55
references: 22980425
references: Hum Gene Ther. 2009 Nov;20(11):1269-78
references: 19619001
references: Clin Cancer Res. 2005 Jun 15;11(12):4460-8
references: 15958631
references: Immunol Rev. 2011 Jan;239(1):62-84
references: 21198665
references: Curr Med Chem. 2006;13(20):2345-52
references: 16918359
references: Leuk Res. 2011 Mar;35(3):369-72
references: 20573399
references: Eur J Haematol. 2010 Oct;85(4):358-60
references: 20633041
references: J Clin Immunol. 2000 May;20(3):195-202
references: 10941827
references: Haematologica. 2010 Jul;95(7):1191-7
references: 20081055
references: Blood. 2010 Jan 21;115(3):653-6
references: 19965687
references: Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5477-82
references: 18375758
references: Cancer Gene Ther. 2008 Feb;15(2):108-14
references: 17992201
references: Cancer Res. 2004 Apr 15;64(8):2858-64
references: 15087404
references: J Int Med Res. 2011;39(3):740-7
references: 21819704
references: Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14646-52
references: 15292504
references: Cancer Biol Ther. 2011 Nov 15;12(10):881-7
references: 22024730
references: Vaccine. 2004 Dec 16;23(5):629-38
references: 15542183